Journal of Clinical Oncology· 2020Q1
Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
- 1,174citations
- Q1SCImago
- 2020year
Short summary
A phase Ib study combining lenvatinib and pembrolizumab in 100 first-line patients with unresectable HCC demonstrated a 46.0% objective response rate (ORR) by modified RECIST, with a median duration of response of 8.6 months.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Hepatology
HepatologyMedicine